SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Leads Biolabs Doses First Patient in Phase I Part B Trial

Leads Biolabs says it dosed the first patient with systemic lupus erythematosus in the Phase I Part B trial of LBL-047.

Related stories